HUCARSG@EC2706A

Keji Pharma-B Plans to Place Up to 23.7M Shares to Raise ~462M HKD for R&D

CARSGEN-B released FY2025 9 Months Earnings on March 6, 2026 (BJT) with actual revenue of HKD 96.01 M and EPS of HKD -0.1703

CARSGEN-B released FY2025 Q3 earnings on March 6 (BJT), actual revenue HKD 40.83 M, actual EPS HKD -0.0221

Keji Pharmaceutical-B Announces 2025 Annual Report, Revenue Up 218.7% Year-over-Year

CARSGEN-B released FY2025 earnings on March 6 After-Market (BJT), actual revenue HKD 137.34 M (forecast HKD 128.23 M), actual EPS HKD -0.1937 (forecast HKD -0.8768)

CARSGEN-B released FY2025 Q4 earnings on March 6 After-Market (BJT), actual revenue HKD 41.53 M, actual EPS HKD -0.0225

CARSGEN-B to Release FY2025 Annual Earnings on March 6, 2026 After-Market (BJT), Forecast Revenue HKD 131.05 M, EPS HKD -0.8961

KeiTheranotics Signs Strategic Cooperation Agreement with Shanghai Jin Gong for Building CAR-T Cell Therapy Product Base

Keji Pharmaceutical Expects Net Loss of No More Than 120 Million Yuan in 2025

Keji Pharmaceutical-B repurchased 326,000 shares for HKD4.8477 million

Guo Huaqing Increases Holdings in Caris Life Sciences to 39.02%

Guo Huaqing Increases Holdings in Celltrion Therapeutics

Keji Pharmaceutical-B repurchases shares and extends plan term; Yi Jie Group 增持 shows confidence

Guo Huaqing Increases Holding of Chi Jun Therapeutics by 30,000 Shares

Keji Pharmaceutical-B repurchased 1,010,000 shares for HKD14.762 million

Keji Pharmaceutical-B Repurchased 1,020,000 Shares

Guo Huaqing Reduced 10,000 Shares of Keji Pharmaceutical

Keji Pharmaceuticals-B Repurchased 173,500 Shares

Non-executive Director Guo Huaqing Buys Shares in Celltrion

Keji Pharmaceutical-B Repurchased 360,000 Shares for HKD 5.9567 Million

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02171

CARSGEN-Bopened 6.48% lower at HKD20.5 after conducting a share placement that raised net proceeds of approximately HKD462 million. The placement involved 23.7 million shares at a price of HKD19.84, a 9.49% discount to the previous closing price of HKD21.92. Short selling reached $18.75M with a ratio of 12.557%. Pre-market trading saw 23.7665 million shares exchanged, totaling HKD472 million.

AASTOCKS News

CARSGEN-B

CARSGEN-B Opens 6.48% Lower on Net Proceeds of HKD462M from Share Placement

159849

159859

Drug Farm announced it will present findings from its Phase 1b study of DF-003, a first-in-class ALPK1 inhibitor, at ARVO 2026. The study showed improvements in visual function and neurological symptoms in patients with ROSAH syndrome. Key findings include reductions in optic disc swelling and gains in visual acuity. DF-003 was well tolerated, with no serious adverse events. The company plans to advance DF-003 into a Phase 3 trial to further evaluate its efficacy and safety. The drug has received multiple FDA designations for its potential in treating ROSAH syndrome and other diseases.

MorningStar

China Merchants CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

512290

588130

513120

159102

516500

159316

159615

159837

CARsgen Therapeutics Holdings Ltd. has scheduled its annual general meeting for May 22, 2026, in Shanghai. Shareholders will vote on adopting the audited financial statements for 2025, re-electing three executive directors, confirming Ernst & Young as auditor, approving director remuneration, and granting a mandate for share issuance. This mandate aims to enhance financial flexibility and support operational needs. The latest analyst rating for CARsgen's stock (HK:2171) is a Hold with a price target of HK$19.00.

Tip Ranks

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CARsgen Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority

560600

588250

A groundbreaking CAR-T cell therapy for advanced gastrointestinal cancers is set to be available in China by mid-2026. Developed for solid tumors targeting Claudin18.2, this therapy, known as satri-cel (CT041), offers a new treatment option for patients with advanced gastric and pancreatic cancers. Clinical studies show a 41% objective response rate and improved progression-free survival compared to standard treatments. This therapy marks a significant advancement in cancer treatment, addressing a major unmet need for patients with limited options.

prnewswire

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

01:28 ETWorld's First CAR-T Therapy for Solid Tumors Available in China Soon

Mainland Chinese investors can now purchase shares in over a dozen newly added Hong Kong-listed biotech companies following a reshuffle of the Stock Connect southbound trading list. Analysts note that while mainland buyers are driving the healthcare rally, foreign capital remains cautious, focusing on select large-cap firms. Notable companies added include Insilico Medicine and CARsGen Therapeutics. Insilico's shares surged over 58% after recent out-licensing deals. The Chinese biotech sector is gaining international recognition, with the government emphasizing its importance as an emerging industry.

SCMP

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

03317

00568

00100

02595

02661

00167

03330

03896

09887

XUNCE(03317) rose 52.37%, with a trading turnover 1.3 Billion HKD, and a year-to-date rose 129.3%. CARSGEN-B(02171) rose 28.06%, with a trading turnover 482.6 Million HKD, and a year-to-date fell 6.3%. SHANDONG MOLONG(00568) rose 25.06%, with a trading turnover 9.1 Billion HKD, and a year-to-date rose 227.4%.

Top Gainers&Losers

XUNCE

SHANDONG MOLONG

MINIMAX-W

GENFLEET-B

QINGSONG HEALTH

IDT INT'L

LINGBAO GOLD

KINGSOFT CLOUD

LEADS BIOLABS-B

Top 10 HK Stock Gainers (3.9)

CARSGEN-B announced its 2025 annual performance, with revenue of 126 million RMB, a year-on-year increase of 218.7%; gross profit was 79.95 million RMB, an increase of 442.1%. The loss narrowed from 798 million RMB in the previous year to 97.86 million RMB, with a loss per share of 0.18 RMB, and no final dividend was declared. The adjusted net loss decreased from 789 million RMB to 77.62 million RMB, mainly due to an increase in other income, a reduction in R&D and administrative expenses, and an increase in gross profit

AASTOCKS

"Performance" CARSGEN's annual loss narrowed to 97.86 million RMB

02659

09900

02637

02652

06869

08279

02910

09936

BAO PHARMA-B(02659) fell 36.63%, with a trading turnover 123.3 Million HKD, and a year-to-date rose 30.8%. ZCLOUD TECH CON(09900) fell 20.21%, with a trading turnover 21.3 Million HKD, and a year-to-date fell 26.1%. HAIXI PHARMA(02637) fell 9.47%, with a trading turnover 15.9 Million HKD, and a year-to-date fell 7.9%.

HUCARSG@EC2706A(29381.HK)

CARSGEN-B Opens 6.48% Lower on Net Proceeds of HKD462M from Share Placement

Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

CARsgen Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority

01:28 ETWorld's First CAR-T Therapy for Solid Tumors Available in China Soon

China investors energise Hong Kong biotech stocks. Is foreign money missing out?